Multitude Therapeutics Inc.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2/3
CD44v9Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
AMT-116Phase 1/2Advanced Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-05-30 · NCT07590531 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
AMT-116Phase 2/3NSCLC (Advanced Non-small Cell Lung Cancer)
Est. primary completion 2028-03-30 · NCT07718737 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.